Pharmaceuticals
December 28, 2022
Raphaël Serreau, Ammar Amirouche, Amine Benyamina et al.
13 citations
Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various Psilocybe-type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the need to develop simple and...
December 27, 2022
James Phelps
A randomized trial of MDMA as an adjunct to psychotherapy for PTSD found it superior to placebo plus the same manualized therapy (effect size 0.9). However, the blinding in that study almost completely failed. Vocal public advocacy for psychedelics as adjuncts to psychotherapy is creating an environment of high positivity bias that is affecting research quality and results. Thus, a recent...
Journal of Affective Disorders
December 27, 2022
Aki Nikolaidis, Rafaelle Lancelotta, Natalie Gukasyan et al.
24 citations
BackgroundSubjective experiences seem to play an important role in the enduring effects of psychedelic experiences. Although the importance of the subjective experience on the impact of psychedelics is frequently discussed, a more detailed understanding of the subtypes of psychedelic experiences and their associated impacts on mental health has not been well documented.MethodsIn the current...
Military Medicine
December 24, 2022
Joshua C. Gray, Mikela A. Murphy, Sierra Carter et al.
10 citations
ABSTRACT Introduction Posttraumatic stress disorder (PTSD) and depression are common in service members and veterans, and the response to currently available treatments is often modest at best. Recent studies suggest potential benefit with psychedelic-assisted therapies (PATs), particularly 3,4-methylenedioxymethamphetamine-assisted therapy for PTSD and psilocybin-assisted therapy for...
Etnografia Polska
December 22, 2022
Zuzanna Sadowska
2 citations
Psychoactive substances are subject to law control, imposed through the system of medical prescription or legal prohibition, with legal penalties for their unauthorized use. The consumption of drugs in a non-medical contexts is often labelled as "drug abuse", and the substance used in this way as a “narcotic” - the term endowed with illegality (Goodman et al. 2017). While legal, medical and...
Social History of Medicine
December 8, 2022
Stephen Lett, Erika Dyck
5 citations
Psychedelic-assisted therapy has attracted considerable clinical attention in the past decade for its ability to bring therapeutic benefits to patients in treatment-resistant categories. In contradistinction from other psychopharmaco-therapies, contemporary psychedelic therapists, like their predecessors, paid close attention to the 'set and setting', and argued that the mind-set of the subject...
Neurosurgery
December 8, 2022
Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi et al.
13 citations
After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and...
Oxford University Press eBooks
December 1, 2022
Stephen Ross, Anthony P. Bossis
Abstract Following a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic therapeutics to alleviate the marked psychic distress in end-of-life cancer patients, major academic centers are resuming contemporary clinical research into the safety and efficacy of psilocybin and other serotonergic psychedelics delivered in...
Contemporary Clinical Trials
December 1, 2022
Kelley C O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et al.
24 citations
Several lines of evidence suggest that classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change in individuals with substance use disorders. We conducted a multi-site, double-blind, randomized controlled trial (RCT) to assess the effects of psilocybin-assisted psychotherapy in alcohol-dependent volunteers. In addition to a...
3 Biotech
December 1, 2022
Dominique Strauss, Soumya Ghosh, Zurika Murray et al.
13 citations
Humans have collected and used hallucinogenic mushrooms for ethnic medicinal, recreational, and religious purposes since before recorded history. Currently, the use of these mushrooms is illegal in most countries, but where their use is legal they are applied as self medication. Psilocybin and psilocin, two psychoactive alkaloids, are naturally synthesized by hallucinogenic mushrooms. The...
Current Psychiatry Reports
December 1, 2022
Natalie Gukasyan, Colleen C Schreyer, Roland R. Griffiths et al.
29 citations
A growing body of research suggests psychedelic-assisted therapy (PAT) may be safe and effective for a variety of mental health conditions. Among these, eating disorders have been a recent target of interest. This review provides an up-to-date summary of the potential mechanisms and use of PAT in people diagnosed with eating disorders, with a focus on anorexia nervosa. Classic psychedelics may...
November 30, 2022
Oliver Davis
8 citations
Psychedelically assisted psychotherapy (PAP) looks set to become a common remedy for a range of serious mental health problems. The market for providing PAP, including a secondary market for the training, credentialising and monitoring of therapists, is expanding rapidly. Concerns have been raised recently by actors in that secondary market about the potential for abuse in PAP, which have been...
Australian & New Zealand Journal of Psychiatry
November 17, 2022
Riccardo Miceli Mcmillan, Anthony Vincent Fernandez
30 citations
Psychedelic-assisted psychotherapy is being investigated as a treatment for a range of psychiatric illnesses. Current research suggests that the kinds of subjective experiences induced by psychedelic compounds play key roles in producing therapeutic outcomes. To date, most knowledge of therapeutic psychedelic experiences are derived from psychometric assessments with scales such as the Mystical...
Journal of Psychopharmacology
November 14, 2022
Meg J. Spriggs, Bruna Giribaldi, Taylor Lyons et al.
15 citations
Background: Psilocybin is a serotonin type 2A (5-HT 2A ) receptor agonist and naturally occurring psychedelic. 5-HT 2A receptor density is known to be associated with body mass index (BMI), however, the impact of this on psilocybin therapy has not been explored. While body weight-adjusted dosing is widely used, this imposes a practical and financial strain on the scalability of psychedelic...
Palliative & Supportive Care
November 3, 2022
Lisa Reynolds, Brian S. Barnett, Jeremy Weleff et al.
19 citations
Abstract Objectives A resurgence of research investigating the administration of psychedelic compounds alongside psychotherapy suggests that this treatment is a promising intervention for anxiety, depression, and existential distress in people with cancer. However, psychedelic treatment that induces a mind-altering experience potentially poses barriers to vulnerable cancer patients, and...
American Journal on Addictions
November 1, 2022
Mariam Kyarunts, Meghna P. Mansukhani, Larissa L. Loukianova et al.
26 citations
AbstractBackground and ObjectivesPatients increasingly rely on the Internet for healthcare information. This study aimed to evaluate the quality of videos on 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for posttraumatic stress disorder (PTSD) on YouTube™.MethodsYouTube™ was searched for the terms “MDMA” and “PTSD.” The 100 most viewed videos were analyzed using three...
Cureus
October 31, 2022
Arafath Mohamed, Shehla Touheed, Muzammil Ahmed et al.
11 citations
Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably, the primary line of treatment for PTSD is psychotherapy, according to current treatment guidelines. However, PTSD continues to be a chronic condition even after psychotherapy, with high psychiatric and medical illness rates. There is a dire need...
October 26, 2022
George Danias, Jacob Appel
BACKGROUND Psychedelic substances have demonstrated promise in the treatment of depression, anxiety, and substance use disorders. Significant media coverage has been dedicated to psychedelic medicine, but it is unclear whether the public associates psilocybin with its potential therapeutic benefits. The COVID-19 pandemic led to an increase in depression, anxiety, and substance abuse in the...
Journal of Psychopharmacology
October 20, 2022
Sascha Thal, Michelle Wieberneit, Jason M. Sharbanee et al.
23 citations
BACKGROUND: Clinical trials are currently investigating the potential of substance-assisted psychotherapy (SAPT) as treatment for several psychiatric conditions. The potential therapeutic effects of SAPT may be influenced by contextual factors including preparation prior to and integration after the substance-assisted therapy sessions. AIMS: This systematized review outlines recommendations for...
Journal of Affective Disorders
October 15, 2022
Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo et al.
Few studies have evaluated the efficacy of ketamine-assisted psychotherapy (KAP) in the treatment of treatment-resistant depression (TRD) and substance use disorders (SUD). A systematic review of clinical trials reporting on the efficacy of KAP and discussing mechanisms of action, identified on PubMed and PsycInfo. Five randomized-controlled trials reported on the efficacy of KAP treatment and...